West Virginia hospital combines cancer, cardiac services to better serve patients

Cabell Huntington Hospital in Huntington, West Virginia, offers a program that combines cancer treatment and cardiac services, a unique initiative among providers, reports the Herald Dispatch.

The program is a joint collaboration between the Marshall Health Departments of Medical Oncology and Cardiology. It’s led by Maria Tirona, MD, an oncologist at the hospital and professor at the Joan C. Edwards School of Medicine, and Ellen Thompson, MD, a cardiologist and an associate professor at the med school.

"Chemotherapy and radiation therapy have revolutionized cancer treatment, but they can lead to potential adverse cardiovascular effects," Tirona said in a release. "Working together in the care of the cancer patient, the goal of the program is to minimize cardiotoxicity during cancer treatment and cardiovascular risks during cancer survival."

To read more about the program, follow the link below:

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.